CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 41 enrolled
Drug / intervention
Olaparib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02787642
NCT02787642Phase 1Completed
CompareCT.gov

A Phase Ib Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma

Institut Bergonié·interventional·Posted Jun 1, 2016·Updated Feb 25, 2026

In Brief

A Phase 1 clinical trial evaluating Olaparib and Concomitant Radiotherapy for Soft-tissue Sarcoma. Completed, enrolled 41 participants across 4 sites.

Detailed Summary

A phase Ib study of Olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft-tissue Sarcoma
CountriesFrance
CollaboratorsNational Cancer Institute, France

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 1, 2016
Enrollment StartJan 1, 2016
Primary CompletionOct 1, 2021
Study CompletionMay 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 10.1 years ago

Interventions

Olaparibdrug

Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.

Concomitant Radiotherapyradiation

Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.